3.3 Diagnostic Prenatal Procedures (Amniocentesis, CVS, PUBS, cfDNA & Ultrasound)

Screening vs. Diagnostic Modalities in Prenatal Genetics

Perinatal nursing demands a clear, precise understanding of the fundamental distinction between prenatal screening tests and invasive diagnostic procedures. All pregnant individuals must be offered both screening and diagnostic options early in pregnancy regardless of maternal age or baseline risk status, supported by pre-test and post-test genetic counseling and shared decision-making.

+-------------------------------------------------------------------------------------------------------------------+
|                                 PRENATAL SCREENING VS. DIAGNOSTIC TESTING MATRIX                                  |
+-------------------------------------------------------------------------------------------------------------------+
  Feature                    Prenatal Screening Modalities                      Invasive Diagnostic Procedures
  -------                    -----------------------------                      ------------------------------
  Primary Modalities         Cell-free DNA (cfDNA/NIPT), Quad Screen,           Chorionic Villus Sampling (CVS),
                             First-Trimester Combined Screen, Ultrasound        Amniocentesis, PUBS (Cordocentesis)
  -------------------------------------------------------------------------------------------------------------------
  Biological Sample          Maternal peripheral venous blood; Ultrasound       Placental trophoblast villi, amniocytes
                             nuchal translucency measurement                    in amniotic fluid, fetal umbilical blood
  -------------------------------------------------------------------------------------------------------------------
  Clinical Objective         Calculates statistical probability / risk ratio    Provides definitive cytogenetic,
                             of a fetal aneuploidy or structural defect         chromosomal microarray, or genomic diagnosis
  -------------------------------------------------------------------------------------------------------------------
  Procedure Loss Risk        Zero procedural risk (non-invasive blood draw)     Low procedural risk (0.1% to 2.0%)
  -------------------------------------------------------------------------------------------------------------------
  Diagnostic Authority       NEVER diagnostic; requires confirmatory testing    Definitive (Gold Standard); guides
                             before irreversible clinical decisions             management, delivery planning, or termination
+-------------------------------------------------------------------------------------------------------------------+

---

Non-Invasive Prenatal Screening: Cell-Free DNA (cfDNA / NIPT)

Cell-Free DNA (cfDNA) screening analyzes small fragments of cell-free extracellular DNA circulating in maternal blood. Approximately 4% to 15% of circulating cell-free DNA in maternal plasma originates from apoptotic placental syncytiotrophoblasts (termed the fetal fraction).

Clinical Specifications

• Timing: Can be drawn at any time starting from 10 0/7 weeks of gestation until term.
• Scope of Screening: Highly sensitive screening for common autosomal trisomies: Trisomy 21 (Down syndrome, >99% detection rate), Trisomy 18 (Edwards syndrome, ~98% detection), and Trisomy 13 (Patau syndrome, ~99% detection), as well as fetal sex and sex chromosome aneuploidies (45,X Turner syndrome; 47,XXY Klinefelter syndrome; 47,XXX; 47,XYY).
• Fetal Fraction Requirement: A minimum fetal fraction of ≥4% is generally required for a valid result. Causes of low fetal fraction (resulting in a 'no-call' or inconclusive test) include early gestational age (<10 weeks), high maternal body mass index (BMI >30–35 kg/m² due to increased maternal plasma volume and adipocyte turnover), maternal use of low-molecular-weight heparin, or underlying fetal aneuploidy (notably Trisomy 13 and Triploidy).
• Mechanisms of Discordant Results (False Positives / False Negatives):
  • Confined Placental Mosaicism (CPM): The genetic mutation exists in placental trophoblasts but not in the fetus proper (or vice versa).
  • Vanishing Twin: Residual apoptotic DNA from a demised co-twin persists in maternal circulation for weeks to months.
  • Maternal Malignancy or Maternal Mosaicism: Undiagnosed maternal chromosomal abnormalities or occult maternal neoplasms shedding abnormal DNA fragments.
  • Clinical Rule: A positive cfDNA screen must always be confirmed via amniocentesis or CVS prior to irreversible pregnancy termination or invasive interventions.

---

Invasive Diagnostic Procedures

1. Chorionic Villus Sampling (CVS)

• Gestational Timing: Performed between 10 0/7 and 13 6/7 weeks of gestation.
• Technique: Under continuous real-time ultrasound guidance, a sterile catheter is inserted transcervically or an 18- to 20-gauge spinal needle is advanced transabdominally into the placenta (chorion frondosum) to aspirate placental chorionic villi.
• Diagnostic Capability: Enables first-trimester karyotyping, chromosomal microarray (CMA), and targeted single-gene molecular testing. Limitation: CVS cannot evaluate for Open Neural Tube Defects (ONTD) because amniotic fluid alpha-fetoprotein cannot be measured; maternal serum alpha-fetoprotein (MSAFP) screening must still be performed at 15–20 weeks.
• Procedure-Related Risks: Pregnancy loss rate of approximately 0.2% to 0.5% (1 in 200 to 1 in 500). If performed prior to 10 0/7 weeks, CVS is associated with severe limb reduction defects (transverse limb deficiency) and micrognathia.

2. Amniocentesis

• Gestational Timing: Performed from 15 0/7 weeks of gestation onward (typically 15 to 20 weeks for genetic evaluation; third trimester for infectious or lung maturity assessment).
• Technique: Under continuous ultrasound visualization, a 20- to 22-gauge spinal needle is advanced transabdominally through the maternal abdominal wall and myometrium into a clear pocket of amniotic fluid, avoiding the fetus and placenta. The initial 1 to 2 mL of fluid is discarded to prevent maternal cell contamination; 15 to 30 mL of clear amniotic fluid is aspirated into sterile, light-shielded syringes.
• Diagnostic Indications and Analysis:
  • Cytogenetics & Genomics: Karyotyping (detects aneuploidies and large translocations; takes 7–14 days) and Chromosomal Microarray (CMA, detects microdeletions and microduplications <5–10 Mb; takes 5–7 days).
  • Open Neural Tube Defects (ONTD): Elevated Amniotic Fluid Alpha-Fetoprotein (AFAFP) confirmed by the presence of Acetylcholinesterase (AChE) is diagnostic for open neural tube defects (anencephaly, myelomeningocele) and ventral wall defects (gastroschisis, omphalocele).
  • Intra-Amniotic Infection (Chorioamnionitis): Fluid analysis showing low glucose (<14 mg/dL), elevated lactate dehydrogenase (LDH), elevated leukocyte count, positive Gram stain, or positive microbial PCR/culture.
  • Fetal Lung Maturity (Historical / Specific Refractory Cases): Lecithin-to-Sphingomyelin (L/S) ratio ≥2.0 and presence of Phosphatidylglycerol (PG) indicates mature fetal surfactant (L/S ≥3.0 in maternal diabetes).
• Procedure-Related Risks: Loss rate is approximately 0.1% to 0.3% (1 in 300 to 1 in 1,000 in modern experienced centers). Complications include transient uterine cramping (1–2%), transient amniotic fluid leakage (1%), intra-amniotic infection (<0.1%), and fetomaternal hemorrhage.

3. Percutaneous Umbilical Blood Sampling (PUBS / Cordocentesis)

• Gestational Timing: Performed after 18 0/7 weeks of gestation.
• Technique: Under direct ultrasound guidance, a 20- to 22-gauge needle is inserted into the umbilical vein at its insertion site into the placenta (where the cord is anchored and immobile).
• Indications: Direct assessment of fetal hematocrit/hemoglobin in severe fetal anemia (due to Rh isoimmunization or parvovirus), emergency fetal platelet transfusion for alloimmune thrombocytopenia, and delivery of Intrauterine Blood Transfusion (IUT) using cross-matched, irradiated, CMV-negative, O-negative packed red blood cells.
• Risks: Highest complication rate among invasive procedures: 1.0% to 2.0% procedure-related loss, cord vessel laceration, cord hematoma, severe refractory fetal bradycardia (often requiring emergency cesarean delivery), and massive fetomaternal hemorrhage.

+-------------------------------------------------------------------------------------------------------------------+
|                                 COMPARISON OF INVASIVE PRENATAL PROCEDURES                                        |
+-------------------------------------------------------------------------------------------------------------------+
  Procedure           Gestational Window     Tissue Sampled        Primary Advantages            Key Limitations
  ---------           ------------------     --------------        ------------------            ---------------
  Chorionic Villus    10 0/7 to 13 6/7 wks   Chorionic Villi       First-trimester diagnosis;    Cannot test for ONTD;
  Sampling (CVS)                             (Placental tissue)    Rapid preliminary FISH        1-2% placental mosaicism
  -------------------------------------------------------------------------------------------------------------------
  Amniocentesis       ≥ 15 0/7 weeks         Amniocytes in         Definitive genetic analysis;  Second trimester timing;
                      (typically 15-20 wks)  Amniotic Fluid        AFAFP & AChE for ONTD;        Loss rate 0.1-0.3%
                                                                   Infection & maturity markers
  -------------------------------------------------------------------------------------------------------------------
  PUBS /              ≥ 18 0/7 weeks         Fetal Umbilical       Direct fetal hematocrit;      Highest loss risk (1-2%);
  Cordocentesis                              Venous Blood          Allows direct intrauterine    Cord hematoma / bradycardia
                                                                   blood transfusion
+-------------------------------------------------------------------------------------------------------------------+

---

Inpatient Obstetric Nursing Care & Safety Protocols

Pre-Procedure Nursing Care

1. Informed Consent & Patient Education: Verify signed informed consent; ensure the patient understands procedural risks, benefits, and diagnostic limitations.
2. Baseline Maternal-Fetal Assessment: Record maternal baseline vital signs. Perform a baseline electronic fetal monitoring (EFM) strip or document fetal heart rate viability via Doppler/ultrasound prior to prep.
3. Bladder Protocol:
   • For early CVS (<12 weeks) or early amniocentesis, a full bladder is often requested to push the anteverted uterus upward into the abdominal field.
   • For second-trimester amniocentesis (≥15 weeks), an empty bladder is mandatory to prevent accidental bladder puncture by the needle.

Intra-Procedure Nursing Responsibilities

• Maintain strict aseptic technique, assist with sterile transducer draping, provide continuous emotional support, and encourage deep relaxation breathing (instructing the patient to avoid sudden body movements or deep coughing during needle insertion).

Post-Procedure Nursing Interventions & Monitoring

1. Post-Procedure Fetal Monitoring: Continuous external EFM (or ultrasound FHR verification) for 30 to 60 minutes post-procedure to evaluate for fetal bradycardia, prolonged decelerations, or loss of variability.
2. Maternal Discharge Instructions: Instruct patient to rest for 24 hours and report immediately for: fever (>100.4°F / 38.0°C), chills, severe persistent uterine cramping, leakage of fluid from the vagina, active vaginal bleeding, or decreased fetal movement.
3. MANDATORY Rho(D) IMMUNE GLOBULIN (RhoGAM) ADMINISTRATION:
   • Any unsensitized Rh-negative pregnant individual undergoing an invasive procedure (CVS, amniocentesis, PUBS, external cephalic version) is at high risk for fetomaternal hemorrhage and isoimmunization.
   • Standard Dosing: Administer 300 mcg (1,500 IU) Rho(D) Immune Globulin intramuscularly within 72 hours of the procedure (50 mcg dose is acceptable for first-trimester procedures before 13 0/7 weeks if 300 mcg is unavailable).